Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01839968
NCT01839968CompletedNot Applicable

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

University Hospital, Geneva1 site in 1 country32 target enrollmentStarted: September 2011Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
32
Locations
1
Primary Endpoint
Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Acute coronary syndrome
  • •Prasugrel loading dose 6-24h before inclusion

Exclusion Criteria

  • •Clopidogrel loading dose
  • •GPIIbIIIa use within 10 days before inclusion
  • •Known congenital thrombopathy and/or congenital coagulation defect

Outcomes

Primary Outcomes

Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition

Time Frame: within the first 6-24 hours after antiplatelet drug loading dose

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Fanny Bonhomme

MD

University Hospital, Geneva

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Reversibility of Dual Antiplatelet Therapy by PlateletsBleeding
NCT01248351Medical University of Graz6
Unknown
Not Applicable
Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)Traumatic Intracranial Hemorrhage
NCT06433622Lancaster General Hospital225
Completed
Phase 2
A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% PlasmaHealthy
NCT02310412Cerus Corporation14
Completed
Phase 4
ASsesment of Platelet function and Inhibition in patients Recovering from severe INfectionHeart attack10011082Acute myocardial infarction
NL-OMON50157Vrije Universiteit Medisch Centrum97
Active, not recruiting
Phase 1
Evaluation of platelet activity in patients recovering from a severe infectioHyperaggregability of thrombocytes triggered by severe infection (i.e. pneumonia or invasive urinary tract infection or a cutaneous infection).
EUCTR2016-004303-32-NLVU university medical center62
Ex-Vivo Reversion of Platelet Inhibition... | Clinical Trial